Company / Working Capital
Syndax Pharmaceuticals Inc Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$408.0M
FY2025
5-year range
$408.0M / $522.8M
FY2021-FY2025
Trend
-18.3%
vs FY2024
Sector context
#106 of 213
Health Care
What the data says
At $408M, Syndax Pharmaceuticals Inc's working capital ranks #106 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $44M in FY2019 to $523M in FY2023.
Based on SEC 10-K filings.
$408M in FY2025 with a 5-year CAGR of +7.8%.
Declined from $523M to $408M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -4.0%
- 5-Year CAGR
- +7.8%
- 10-Year CAGR
- -
Sector benchmark
#106 of 213 in Health CareTop 50% of 213This company $408.0M Sector average $934.6M
▼
-56.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.8%, indicating consistent growth.
- In FY2025, working capital decreased 18.3% year-over-year.
- Ranks #106 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $408.0M | -18.3% |
| FY2024 | $499.5M | -4.5% |
| FY2023 | $522.8M | +13.5% |
| FY2022 | $460.7M | +7.7% |
| FY2021 | $427.7M | +52.8% |
| FY2020 | $280.0M | +536.9% |
| FY2019 | $44.0M | -34.6% |
| FY2018 | $67.2M | -42.8% |
| FY2017 | $117.6M | +19.9% |
| FY2016 | $98.1M | +18.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026